Wipro and Avesthagen have entered into a four-year strategic alliance, for making Avesthagen’s genetic testing portfolio commercial. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.
Together, Avesthagen and Wipro will execute the project titled, ‘Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer Project related Genomics Sequencing services.’ The Project will be jointly led by Avesthagen and Wipro where Wipro’s state-of-the-art Lifesciences lab will perform initial processing of the samples, generate data on the latest Next-generation sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML based tools.
Wipro is a leading global information technology, consulting and business process services company.
